Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML
Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML
Active, not recruiting · NCT04953780 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT04953780 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| West Virginia University | 58 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Greenebaum Cancer Center, University of Maryland Medical Systems | Baltimore | United States | 1 |
| West Virginia University | Morgantown | United States | 87 |